Breaking News

Tweet TWEET

NuVasive(R) Named One of the Fastest Growing Technology Companies in North America on Deloitte's 2013 Technology Fast 500(TM)

NuVasive(R) Named One of the Fastest Growing Technology Companies in North 
America on Deloitte's 2013 Technology Fast 500(TM) 
SAN DIEGO, CA -- (Marketwired) -- 11/26/13 --  NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
is excited to announce that NuVasive was named one of the fastest
growing companies on Deloitte's Technology Fast 500(TM) list, a
ranking of the 500 fastest growing technology, media,
telecommunications, life sciences and clean technology companies in
North America. Rankings are based on the percentage revenue growth
over five years from 2008 to 2012, during which NuVasive demonstrated
a compound annual revenue growth rate of 25 percent. 
NuVasive Chairman and Chief Executive Officer, Alex Lukianov, credits
the Company's market share taking strategy, driven by Speed of
Innovation(R) and Absolute Responsiveness(R) with NuVasive's industry
leading growth.  
"I am very proud that NuVasive has been recognized by Deloitte as one
of the fastest growing technology companies in North America," said
Alex Lukianov. "The achievement is a direct result of our culture of
outstanding A-player standards, game-changing products and
procedures, and most importantly, a company-wide mission to deliver
better outcomes to spine patients around the globe." 
"The 2013 Deloitte Technology Fast 500 companies are exemplary cases
of those spurring growth in a tough market through innovation," said
Eric Openshaw, vice chairman, Deloitte LLP and U.S. technology, media
and telecommunications leader. "This year's list is a who's who of
companies behind the most exciting and innovative products and
services in the technology space. We congratulate the Fast 500
companies and look forward to learning of what they will do next." 
"The fastest growing companies in the U.S. are drivers of constant
innovation and operate with the agility to stay ahead of a quickly
evolving marketplace. Software, biotech, pharma, medical device and
internet companies continue to be at the forefront," added James
Atwell, national managing partner of the Emerging Growth Company
practice, Deloitte Services LP. "The companies excelling in these
sectors have a startup mentality that allows them to be nimble and
adapt quickly, which is why they consistently lead the list of
fast-growing companies each year." 
In addition to Deloitte's Fast 500 acknowledgment, NuVasive was also
recognized by the 2013 Ernst and Young Global Medical Technology
Report as once again leading the U.S. public medtech industry with
the highest five-year revenue growth rate.  
About Deloitte's 2013 Technology Fast 500(TM) 
Technology Fast 500, conducted by Deloitte LLP, provides a ranking of
the fastest growing technology, media, telecommunications, life
sciences and clean technology companies -- both public and private --
in North America. Technology Fast 500 award winners are selected
based on percentage fiscal year revenue growth from 2008 to 2012. 
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000 USD or CD, and current-year
operating revenues of at least $5 million USD or CD. Additionally,
companies must be in business for a minimum of five years and be
headquartered within North America. 
About NuVasive 
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market. 
NuVasive offers a comprehensive spine portfolio of over 80 unique
products developed to improve spine surgery and patient outcomes. The
Company's principal procedural solution is its Maximum Access
Surgery, or MAS(R) platform for lateral spine fusion. MAS provides
safe, reproducible, and clinically proven outcomes, and is a highly
differentiated solution with fully integrated neuromonitoring,
customizable exposure, and a broad offering of application-specific
implants and fixation devices designed to address a variety of
pathologies.  
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasive solutions. The Company's dedication to innovation
continues to spawn game changing technology such as the PCM(R) motion
preserving disc for the cervical spine, XLIF(R) Corpectomy for tumor
and trauma, and Armada(R), which treats adult degenerative scoliosis
in a less invasive fashion. The Company has also developed procedural
solutions that completely redefine and improve upon traditional
procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's
solutions are increasingly being adopted internationally, as the
Company lays the groundwork to continue growing as a global business
and to offer industry-leading, Absolutely Responsive customer service
to surgeons world-wide. NuVasive is focused on becoming a $1 Billion
Start-Up(TM); taking market share by maintaining a commitment to
Superior Clinical Outcomes, Speed of Innovation(R), and Absolute
Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties are described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
investorrelations@nuvasive.com  
Media Contact:
Nicole Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com 
 
 
Press spacebar to pause and continue. Press esc to stop.